Scilex Pharms Inc   Report issue

For profit Phase 1 Phase 4
Founded: San Diego CA United States (2011)
Status: Acquired by Sorrento Therapeutics, Inc. (2016)

Organization Overview

First Clinical Trial
2014
NCT04144192
First Marketed Drug
2018
lidocaine (xylocaine)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Scilex Ltd. | Scilex Pharmaceuticals, Inc. | SCILEX PHARMS INC

Active Ingredients

Marketed Drugs (1)

lidocaine (xylocaine) (2018)

Drugs in Phase 4 Trials (1)

lidocaine (xylocaine) (12 trials)

Drugs in Phase 1 Trials (3)

menthol (Salonpas) (1 trial)

naltrexone (revia) (2 trials)

sp-104 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carpal Tunnel Syndrome (Phase 4)

Syndrome (Phase 4)

Tissue Adhesions (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 4